Fennec Pharmaceuticals Inc.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
402.7M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Healthcare
Biotechnology
TSX
Key Financial Metrics
47.5M
Revenue
-436,000
Net Income
-
EPS (Diluted)
27.0M
Free Cash Flow
Profitability
Gross Margin
93.3%
Operating Margin
5.2%
Net Profit Margin
-0.9%
EBITDA
4.8M
Returns & Efficiency
Return on Assets (ROA)
-1.0%
Return on Equity (ROE)
-
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
44.9M
Total Debt
19.3M
Debt to Equity
-
Current Ratio
6.38
Company Info
| Industry | Biotechnology |
| HQ | Research Triangle Park, United States |
| Employees | 32 |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | fennecpharma.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
1,703,980
Shares Sold
0
Total Transactions
50
SEDAR+ Filings
View All Filings3
Annual Reports
24
Quarterly Reports
26
MD&A
77
News Releases
14
Material Changes
2
Prospectuses
10
Governance
55
Certifications
60
Other
●
2024-04-01
●
2024-04-01
●
2021-03-30
●
2017-11-22
●
2017-10-26
Interactive Charts
Company Profile
General Information
| Company Name | Fennec Pharmaceuticals Inc. |
| Ticker | FRX.TO |
| Exchange | TSX |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Research Triangle Park, United States |
| Employees | 32 |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | fennecpharma.com |
Financial Summary
| Market Cap | 402.7M |
| Revenue | 47.5M |
| Net Income | -436,000 |
| P/E Ratio | N/A |
| EPS (Diluted) | N/A |
| Net Margin | -0.9% |
| ROE | N/A |
| Dividend Yield | N/A |
Business Description
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.